Showing results (211-220 of 243) with videos related to
Sort By:
Pageof 25
Anticancer Research|July 25, 1998
A phase II study of neoadjuvant chemotherapy with cisplatin epirubicin and VP-16 for stage III unresectable non-small cell lung cancerS Iacobelli, L Irtelli, R Sacco, et al.Oncogenesis|September 2, 2014
Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancerR Lattanzio, R Ghasemi, F Brancati, et al.Journal of Hepatology|August 1, 1996
Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patientsM Artini, C Natoli, N Tinari, et al.Cancer|June 1, 1988
Effects of antiestrogen and progestin on immune functions in breast cancer patientsG Scambia, P B Panici, A Maccio, et al.Anticancer Research|February 24, 2001
Peritoneal mesothelial cells as a significant source of ascitic immunostimulatory protein 90KA G Zeimet, S Stadlmann, C Natoli, et al.Biochimica Et Biophysica Acta|March 5, 2011
Unknown primary tumorsC Natoli, V Ramazzotti, O Nappi, et al.Cancer Research|February 15, 1991
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cellsA Budillon, P Tagliaferri, M Caraglia, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?E Bajetta, L Catena, G Procopio, et al.Toxicology Letters|November 26, 2009
Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in miceC Ahowesso, E Piccolo, X M Li, et al.Archives of Pathology & Laboratory Medicine|March 14, 1998
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10(6) cells/LN Tinari, C Natoli, N D'Ostilio, et al.Pageof 25